- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Denali Therapeutics Inc (4DN)Denali Therapeutics Inc stock price live, this page displays NASDAQ DNLI stock exchange data. View the DNLI premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Denali Therapeutics Inc real time stock price chart below.
What Is the Denali Therapeutics Inc Stock Price Today?
The Denali Therapeutics Inc stock price today is 22.5800.
What Is the Stock Symbol for Denali Therapeutics Inc?
The stock symbol for Denali Therapeutics Inc is "DNLI."
What Stock Exchange Does Denali Therapeutics Inc Trade On?
Denali Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Denali Therapeutics Inc a Good Stock to Buy?
Determining whether Denali Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DNLI quote. (ISIN: US24823R1059)
What Is the Denali Therapeutics Inc Stock Price Today?
The Denali Therapeutics Inc stock price today is 22.5800.
What Is the Stock Symbol for Denali Therapeutics Inc?
The stock symbol for Denali Therapeutics Inc is "DNLI."
What Stock Exchange Does Denali Therapeutics Inc Trade On?
Denali Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Denali Therapeutics Inc a Good Stock to Buy?
Determining whether Denali Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DNLI quote. (ISIN: US24823R1059)
22.5800
-1.7000(-7.00%)
Delayed Data
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
22.5800
22.5800
52 wk Range
13.9400
29.6700
4DN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
22.580022.5800
52 wk Range
13.940029.6700
Key Statistics
Edit
Fair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
Unlock4DN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Price Target
42.0800
Upside
+77.1044%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
7 analysts have revised their earnings downwards for the upcoming period
Denali Therapeutics Inc Company Profile
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Compare 4DN to Peers and Sector
Metrics to compare | 4DN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4DNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.0x | −2.1x | −0.7x | |
PEG Ratio | 0.04 | 0.00 | 0.00 | |
Price/Book | 2.6x | 2.5x | 2.6x | |
Price / LTM Sales | - | 28.9x | 3.2x | |
Upside (Analyst Target) | - | 306.6% | 46.4% | |
Fair Value Upside | Unlock | 12.0% | 6.9% | Unlock |
People Also Watch
FAQ
What Is the Denali Therapeutics (4DN) Stock Price Today?
The Denali Therapeutics stock price today is 22.58
What Stock Exchange Does Denali Therapeutics Trade On?
Denali Therapeutics is listed and trades on the Frankfurt stock exchange.
What Is the Stock Symbol for Denali Therapeutics?
The stock symbol for Denali Therapeutics is "4DN."
What Is the Denali Therapeutics Market Cap?
As of today, Denali Therapeutics market cap is 3.24B.
What is Denali Therapeutics Earnings Per Share?
The Denali Therapeutics EPS is -2.73.
From a Technical Analysis Perspective, Is 4DN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.